Is Enovix an Underrated Small Cap?
Enovix (NASDAQ:ENVX) is one of several small, innovative companies hoping…
Sell
41
MEDIF Quote, Financials, Valuation and Earnings
Last price:
$0.07
Seasonality move
:
-13.54%
Day range:
$0.06 - $0.07
52-week range:
$0.04 - $0.09
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.88x
P/B ratio:
0.90x
Volume:
88.2K
Avg. volume:
98.3K
1-year change:
9.27%
Market cap:
$27.1M
Revenue:
$30.6M
EPS (TTM):
-$0.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MEDIF
MediPharm Labs
|
$7.4M | -- | 2.62% | -- | -- |
|
AUPH
Aurinia Pharmaceuticals
|
$61.1M | $0.10 | 12.73% | 1025% | $9.83 |
|
EDSA
Edesa Biotech
|
-- | -- | -- | -- | $19.00 |
|
EPIX
ESSA Pharma
|
-- | -$0.19 | -- | -54.86% | $1.68 |
|
LEXX
Lexaria Bioscience
|
$91.3K | -- | 107.14% | -- | $7.00 |
|
XENE
Xenon Pharmaceuticals
|
$1.9M | -$0.90 | -- | -31.27% | $57.18 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MEDIF
MediPharm Labs
|
$0.07 | -- | $27.1M | -- | $0.00 | 0% | 0.88x |
|
AUPH
Aurinia Pharmaceuticals
|
$8.00 | $9.83 | $1.1B | 160.00x | $0.00 | 0% | 4.96x |
|
EDSA
Edesa Biotech
|
$2.05 | $19.00 | $14.4M | -- | $0.00 | 0% | 20.23x |
|
EPIX
ESSA Pharma
|
$1.72 | $1.68 | $76.3M | -- | $0.00 | 0% | -- |
|
LEXX
Lexaria Bioscience
|
$1.08 | $7.00 | $21.1M | -- | $0.00 | 0% | 32.73x |
|
XENE
Xenon Pharmaceuticals
|
$35.02 | $57.18 | $2.7B | -- | $0.00 | 0% | 207.11x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MEDIF
MediPharm Labs
|
1.25% | -2.760 | 2.06% | 1.84x |
|
AUPH
Aurinia Pharmaceuticals
|
-- | 1.242 | -- | 4.04x |
|
EDSA
Edesa Biotech
|
-- | -0.678 | -- | -- |
|
EPIX
ESSA Pharma
|
-- | -2.507 | -- | -- |
|
LEXX
Lexaria Bioscience
|
-- | 0.015 | -- | 3.77x |
|
XENE
Xenon Pharmaceuticals
|
-- | 0.566 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MEDIF
MediPharm Labs
|
$2.3M | -$2M | -22.42% | -23.29% | -25.91% | -$516.2K |
|
AUPH
Aurinia Pharmaceuticals
|
$54.3M | $13.7M | 1.54% | 1.54% | 3.87% | $30.1M |
|
EDSA
Edesa Biotech
|
-- | -$1.6M | -- | -- | -- | -$1.5M |
|
EPIX
ESSA Pharma
|
-- | -$9.9M | -- | -- | -- | -$6.5M |
|
LEXX
Lexaria Bioscience
|
$174K | -$2.8M | -118.15% | -118.15% | -1581.04% | -$1.5M |
|
XENE
Xenon Pharmaceuticals
|
-- | -$77.5M | -- | -- | -- | -$55.2M |
MediPharm Labs vs. Competitors
-
Which has Higher Returns MEDIF or AUPH?
Aurinia Pharmaceuticals has a net margin of -28.31% compared to MediPharm Labs's net margin of 2.39%. MediPharm Labs's return on equity of -23.29% beat Aurinia Pharmaceuticals's return on equity of 1.54%.
Company Gross Margin Earnings Per Share Invested Capital MEDIFMediPharm Labs31.84% -$0.01 $33.8M AUPHAurinia Pharmaceuticals90.73% $0.01 $377.5M -
What do Analysts Say About MEDIF or AUPH?
MediPharm Labs has a consensus price target of --, signalling downside risk potential of --. On the other hand Aurinia Pharmaceuticals has an analysts' consensus of $9.83 which suggests that it could grow by 22.92%. Given that Aurinia Pharmaceuticals has higher upside potential than MediPharm Labs, analysts believe Aurinia Pharmaceuticals is more attractive than MediPharm Labs.
Company Buy Ratings Hold Ratings Sell Ratings MEDIFMediPharm Labs0 0 0 AUPHAurinia Pharmaceuticals3 1 0 -
Is MEDIF or AUPH More Risky?
MediPharm Labs has a beta of 0.271, which suggesting that the stock is 72.939% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals has a beta of 1.160, suggesting its more volatile than the S&P 500 by 16.034%.
-
Which is a Better Dividend Stock MEDIF or AUPH?
MediPharm Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs pays -- of its earnings as a dividend. Aurinia Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEDIF or AUPH?
MediPharm Labs quarterly revenues are $7.2M, which are smaller than Aurinia Pharmaceuticals quarterly revenues of $59.9M. MediPharm Labs's net income of -$2M is lower than Aurinia Pharmaceuticals's net income of $1.4M. Notably, MediPharm Labs's price-to-earnings ratio is -- while Aurinia Pharmaceuticals's PE ratio is 160.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs is 0.88x versus 4.96x for Aurinia Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEDIFMediPharm Labs0.88x -- $7.2M -$2M AUPHAurinia Pharmaceuticals4.96x 160.00x $59.9M $1.4M
-
Which has Higher Returns MEDIF or EDSA?
Edesa Biotech has a net margin of -28.31% compared to MediPharm Labs's net margin of --. MediPharm Labs's return on equity of -23.29% beat Edesa Biotech's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MEDIFMediPharm Labs31.84% -$0.01 $33.8M EDSAEdesa Biotech-- -$0.48 -- -
What do Analysts Say About MEDIF or EDSA?
MediPharm Labs has a consensus price target of --, signalling downside risk potential of --. On the other hand Edesa Biotech has an analysts' consensus of $19.00 which suggests that it could grow by 829.1%. Given that Edesa Biotech has higher upside potential than MediPharm Labs, analysts believe Edesa Biotech is more attractive than MediPharm Labs.
Company Buy Ratings Hold Ratings Sell Ratings MEDIFMediPharm Labs0 0 0 EDSAEdesa Biotech0 0 0 -
Is MEDIF or EDSA More Risky?
MediPharm Labs has a beta of 0.271, which suggesting that the stock is 72.939% less volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.291%.
-
Which is a Better Dividend Stock MEDIF or EDSA?
MediPharm Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEDIF or EDSA?
MediPharm Labs quarterly revenues are $7.2M, which are larger than Edesa Biotech quarterly revenues of --. MediPharm Labs's net income of -$2M is lower than Edesa Biotech's net income of -$1.6M. Notably, MediPharm Labs's price-to-earnings ratio is -- while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs is 0.88x versus 20.23x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEDIFMediPharm Labs0.88x -- $7.2M -$2M EDSAEdesa Biotech20.23x -- -- -$1.6M
-
Which has Higher Returns MEDIF or EPIX?
ESSA Pharma has a net margin of -28.31% compared to MediPharm Labs's net margin of --. MediPharm Labs's return on equity of -23.29% beat ESSA Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MEDIFMediPharm Labs31.84% -$0.01 $33.8M EPIXESSA Pharma-- -$0.19 -- -
What do Analysts Say About MEDIF or EPIX?
MediPharm Labs has a consensus price target of --, signalling downside risk potential of --. On the other hand ESSA Pharma has an analysts' consensus of $1.68 which suggests that it could fall by -2.25%. Given that ESSA Pharma has higher upside potential than MediPharm Labs, analysts believe ESSA Pharma is more attractive than MediPharm Labs.
Company Buy Ratings Hold Ratings Sell Ratings MEDIFMediPharm Labs0 0 0 EPIXESSA Pharma0 2 0 -
Is MEDIF or EPIX More Risky?
MediPharm Labs has a beta of 0.271, which suggesting that the stock is 72.939% less volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.686, suggesting its more volatile than the S&P 500 by 68.618%.
-
Which is a Better Dividend Stock MEDIF or EPIX?
MediPharm Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEDIF or EPIX?
MediPharm Labs quarterly revenues are $7.2M, which are larger than ESSA Pharma quarterly revenues of --. MediPharm Labs's net income of -$2M is higher than ESSA Pharma's net income of -$8.5M. Notably, MediPharm Labs's price-to-earnings ratio is -- while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs is 0.88x versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEDIFMediPharm Labs0.88x -- $7.2M -$2M EPIXESSA Pharma-- -- -- -$8.5M
-
Which has Higher Returns MEDIF or LEXX?
Lexaria Bioscience has a net margin of -28.31% compared to MediPharm Labs's net margin of -1559.32%. MediPharm Labs's return on equity of -23.29% beat Lexaria Bioscience's return on equity of -118.15%.
Company Gross Margin Earnings Per Share Invested Capital MEDIFMediPharm Labs31.84% -$0.01 $33.8M LEXXLexaria Bioscience98.52% -$0.15 $6.8M -
What do Analysts Say About MEDIF or LEXX?
MediPharm Labs has a consensus price target of --, signalling downside risk potential of --. On the other hand Lexaria Bioscience has an analysts' consensus of $7.00 which suggests that it could grow by 548.15%. Given that Lexaria Bioscience has higher upside potential than MediPharm Labs, analysts believe Lexaria Bioscience is more attractive than MediPharm Labs.
Company Buy Ratings Hold Ratings Sell Ratings MEDIFMediPharm Labs0 0 0 LEXXLexaria Bioscience0 0 0 -
Is MEDIF or LEXX More Risky?
MediPharm Labs has a beta of 0.271, which suggesting that the stock is 72.939% less volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 1.008, suggesting its more volatile than the S&P 500 by 0.806%.
-
Which is a Better Dividend Stock MEDIF or LEXX?
MediPharm Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEDIF or LEXX?
MediPharm Labs quarterly revenues are $7.2M, which are larger than Lexaria Bioscience quarterly revenues of $174K. MediPharm Labs's net income of -$2M is higher than Lexaria Bioscience's net income of -$2.7M. Notably, MediPharm Labs's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs is 0.88x versus 32.73x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEDIFMediPharm Labs0.88x -- $7.2M -$2M LEXXLexaria Bioscience32.73x -- $174K -$2.7M
-
Which has Higher Returns MEDIF or XENE?
Xenon Pharmaceuticals has a net margin of -28.31% compared to MediPharm Labs's net margin of --. MediPharm Labs's return on equity of -23.29% beat Xenon Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MEDIFMediPharm Labs31.84% -$0.01 $33.8M XENEXenon Pharmaceuticals-- -$0.84 -- -
What do Analysts Say About MEDIF or XENE?
MediPharm Labs has a consensus price target of --, signalling downside risk potential of --. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $57.18 which suggests that it could grow by 63.27%. Given that Xenon Pharmaceuticals has higher upside potential than MediPharm Labs, analysts believe Xenon Pharmaceuticals is more attractive than MediPharm Labs.
Company Buy Ratings Hold Ratings Sell Ratings MEDIFMediPharm Labs0 0 0 XENEXenon Pharmaceuticals13 0 0 -
Is MEDIF or XENE More Risky?
MediPharm Labs has a beta of 0.271, which suggesting that the stock is 72.939% less volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.212, suggesting its more volatile than the S&P 500 by 21.174%.
-
Which is a Better Dividend Stock MEDIF or XENE?
MediPharm Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEDIF or XENE?
MediPharm Labs quarterly revenues are $7.2M, which are larger than Xenon Pharmaceuticals quarterly revenues of --. MediPharm Labs's net income of -$2M is higher than Xenon Pharmaceuticals's net income of -$65.7M. Notably, MediPharm Labs's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs is 0.88x versus 207.11x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEDIFMediPharm Labs0.88x -- $7.2M -$2M XENEXenon Pharmaceuticals207.11x -- -- -$65.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Are We Heading Toward a Recession?
Fears of a recession in 2025 grew at the end…
3 Recession-Proof ETFs to Invest in Now
The U.S. gross domestic product (GDP) contracted 0.3% during the…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 12
Regencell Bioscience Holdings [RGC] is up 3.14% over the past day.
Buy
97
NGVC alert for May 12
Natural Grocers by Vitamin Cottage [NGVC] is down 1.41% over the past day.
Sell
38
ONTO alert for May 12
Onto Innovation [ONTO] is up 5.21% over the past day.
